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Liver kansplantation in CF: lO-year experience at a supra-regional 
liver cenke 
F.M. B art lett 1, S. Hegde 1, R.G.G. Ruiz  1, H.A. Wyatt 1, N.D. Heat on 2, M. Rela 2, J.F. 
Price 1 
~RegionaI Cystic Fibrosis Service, King's College Hospital, Lo~ulo~ UK, 2Institute 
of Liver Studies, King's College Hospital, Lo~ulo~ UK 
In rmduet lon :  Current knowledge of orthotopic l iver tranrplantation (OLT) in CF 
comes from a few small series. We present our experience. 
Methods:  Retrorpective review of cases conridered for OLT in the last 10 yearr. 
Mid  upper arm circumference (MAC) war  the primary nutrit ional outcome 
parameter ar pre tranrplant f lu id retention and organomegaly complicated 
interpretation of weight. Respiratory rtatur war  arrerred by FEV 1. 
Results: 21 patients were arrerred for OLT. 9 were conridered unsuitable due to: 
severe lung disease (4), psychological dirturbance (3), non tuberculour 
mycobacterial infection (1), active aspergillorir (1). 5 of there non~ranrplanted 
patients have rince died from respiratory failure. A further patient died of variceal 
haemordaage when lifted. 11 patients (6 males) received 13 graftr. The median 
(range) age at tranrplant a ion war  14.5 (7.8 30.5) yearr. Al l  s~ar vived at least 1year. 
3 patients died; 2 from complications of immtmorupprerrion angioinvarive 
arpergil lorir (after 38 months) and lymphoproliferative disease (35 monthr). The 
third died from complications of long term non adherence (after 52 months). The 
remaining 8 have fur vived a median (range) of 46 (12 109) monthr. Al l  but 2 have 
shown an improvement in MAC. FEV~ % predicted range immediately pre OLT 
war  45 79%. Rerpiratot3, rtatur hat general ly rtabil ired or improved post OLT. 
Conclusion: Liver t anrplant a ion for selected CF patients in our centre hat a 100% 
1 year rurvival and currently 88% of recipientr are alive. Nutrit ional outcome ir 
also good. Our careful confider ation of pre~exir t ing lung disease and psychological 
state before tranrplant a ion may have influenced thir outcome. 
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Pancreatic phenotype in CF infants idenEfied by two neonatal 
mutational screening programs 
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The current rtudy war  derigned to evaluate the pancreatic phenotype of a large 
group of CF infantr diagnored by two mutational neonatal rcreening (NS) 
programr. Al l  CF infantr diagnored by NS during a 9 "fear rpan at the Verona CF 
Centre (VCFC) Italy, and thore referred to the Children'r Horpital at Wertmead 
(CHW) ha Sydney from the NS program of New South Waler (NSW) Aurtral ia, 
were included. In the CHW only F508del war terted (72% detection rate), in the 
VCFC more mutationr were included (79% detection rate of revere mutationr). 
C I~V had a greater number of F508del homozygoter than VCFC (89 vr 37, 
p < 0.C~)1), VCFC had a greater number of F508del compound heter ozygoter (67 vr 
57, p < 0.025) and non F508del ptr (45 vr 19, p < 0.001). Pancreatic function 
assessment by 3 5 day fat balance rtudier and/or pancreatic stimulation tests 
demonrtrated that 82/315 (26%) were PS, with r imilar proportionr of PS ha NSW 
and Veneto (29% vr 23%, p 0.43). Twelve ptr ha NSW and 6 ha Veneto who were 
initial ly PS became PI at varying times from 2 monthr to 5 yearr of age. There 18 
(22%) were F508del/F508del, or F508del/revere mutation. In conclusion, a large 
proportion of CF infantr diagnored by mutational rcreening have normal fat 
absorption. Thir finding, which appearr independent of geographical location mad 
genetic background, empharizer the necerrity of determing pancreatic phenotype 
and thur enrur ing appropriate therapy for PI patients whi le  avoiding unnecerrary 
treatments in PS patients. 
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Liver  tranrplantat ion (Tx) ir  conridered an effective treatment for portal 
hyper tenrion mad revere hepatic dysfunction in CF without advanced lung direare. 
A im:  to verify the change in FEV1 ha CF after Tx. Methodr: FEV1 before and after 
Tx were compared (mort recent FEV 1 before Tx compared with firrt FEV 1 after Tx 
with a stable cl inical condition). Rerultr:  5 Tx rince Apr i l /02 :4  boyr and 1 girl. 
Mean age: 13.98 yearr (17, 10, 10, 14 and 17 yearr). Al l  patientr colonized with/~ 
aeruginosa, 1 B.cepacia and2 MRSA. One had iabeter before Tx; 3 developed 
diabeter after Tx. A l l  fur r ived. One developed revere deprer ion and could perform 
an adequate rpirometry only 15 monthr after Tx. FEV1 before Tx war 84.81%, 
71.51%, 74.14%, 71.33% and 104.58%, rerpectively. FEV1 changer were variable: 
2 got worre e 3 got better: (A ~i3.40%, +5.76%, 28.52%, +4.18% and +7.25%, 
after 15, 8, 4, 4 and 5 monthr ofTx,  rerpectively). Mean change war  8.72 %. The 
worrt changer were found in one patient colonized with B.cepacia and MRSA for 
10 yearr, good FEV1, radiological rcore and compliance before Tx, but who 
developed a deprer ive dir order mad no compliance after Tx and in one patient who 
developed a hepatic hydrothorax with chert drainage mad pulmonary infection. 
Conclurionr: Tx can improve pulmonary function and be wel l  tolerated in relected 
patientr with CF. Ber ider cl inical and laboratory analyrir, intenrive prychological 
evaluation ir errential,  mainly during the adolercence. Pulmonary direare ir  rti l l  
prerent, ro the patient hat to cooperate with the treatment ar much ar partible. I f  
pulmonary involvement ir  revere, combined lung and liver tranrplantation rhould 
be conridered. 
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Discrepancies between exocrine pancreatic status and enzyme 
therapy in CF-patients 
L. Naehr l ich 
University hospital for children a~ul adolescents, Erlangen/Germany 
Aims:  The german CF regirtry reportr that 93% of all patientr were treated with 
pancreatic enzymer, but only 77% were judged ar pancreatic inrufficient. To 
determine dircrepancier between enzyme therapy and exc~rine pancreatic function 
we mearured faecal pancreatic elartare (FE 1), a highly renrit ive and rpecific 
rcreening tert to classify exc~rine pancreatic rtatur. 
Methods:  ha a cohort rtudy rtool rampler were analyzed for FE 1 with the ure of 
human monc~lonale (Schebo, Gierren/Germany) or polyclonale (Biorerv, 
Rot tc¢ldGer many ) ELISA tertr. Pancreatic rufficiency war  defined ar having FE 1 
> 2C~) ~tg/g rtool. The initial treatment decirion for pancreatic enzymer war bared 
on clinical r ight of rteatorrhoea. 
Results: We mearured FE 1 ha 117 patientr (age between 6 weeks and 42 yearr 
(median 11,6 yearr)). 54% of our patient r were homozygour, 39% heter ozygote for 
F508 and 7% had two Non F508 mut ationr. A hirtory of meconiumileur ir poritive 
in 18% of our population. Fe 1 war  meas~ared < 1C~)~tg/g rtool in 53%, between 100 
and 2C~) ~tg/g rtool ha 29% and > 2C~) ~tg/g stool ha 18% our rampler. Only tbree 
patientr have a FE 1 > 5C~)~tg/g rtool. In 45% the FE 1 value war  between 100 and 
300 pg/g rtool. 6 out of 96 pancreatic ins~afficient patientr (definition: Fe 1 < 200 
~tg/g rtool) do not take enzymer ha contrart to the medical advice. 14 out 21 patient r 
with an FE 1 > 2C~)~t g/g rtool were treated with enzymer. 
Concluslous: According to the FE 1 mearurementr 82% of our patientr are 
pancreatic rufficient, ha contrart o other rtudier 45% of all FE 1 valuer are between 
100 mad 3C~)~tg/g rtool. In 18% of our patientr dircrepancier between the exc~rine 
pancreatic rtatur bared on FE 1 and the pancreatic enzymer therapy could be 
detected. 
